DATUM / RESEARCH-CONTEXT DOSING
BPC-157 Dosage as the Studies Express It
Research-context figures only — what was administered, to which species, by which route. No human protocol exists; the doses below are study readouts, not guidance.
How BPC-157 Doses Are Expressed in the Research
BPC-157 dosage in the literature is expressed as a research figure tied to a species and a route — never as a human protocol, because no validated human protocol exists [6]. Rodent studies commonly express dose per body weight, frequently around 10 microg/kg and 10 ng/kg, and as low as 10 pg in some tendon work [1]. Gastric-ulcer cytoprotection was studied at 400 ng/kg and 800 ng/kg in rats [4].
Human exposure data are minimal: a two-person intravenous safety pilot used 10 mg then 20 mg by infusion [5], and an interstitial-cystitis pilot used a single 10 mg dose intravesically [8]. These are the amounts administered in specific studies — they are reported here so the literature can be read accurately, not as a recommendation for any person.
BPC-157 Injection Routes Used in Studies
BPC-157 injection in research spans several routes. The most common in rodent work is intraperitoneal, used in the transected-Achilles tendon study at once-daily dosing [1]. Intramuscular and intragastric routes were directly compared in the gastric-ulcer model, where intramuscular delivery outperformed intragastric [4]. Local and intra-lesional administration has also been tested [1].
In humans, the three pilots used intravenous infusion [5], intravesical instillation during cystoscopy [8], and intra-articular injection into the knee [7]. Each route appears in a distinct study; none has an established human dose.
BPC-157 Half-Life in Animal Pharmacokinetics
BPC-157's elimination half-life is reported as under 30 min for the prototype peptide in a rat and dog pharmacokinetic study, after both intravenous and intramuscular administration [2]. The same study found linear pharmacokinetics and intramuscular bioavailability of roughly 14-19% in rats and 45-51% in dogs, with rapid breakdown into small peptide fragments [2]. There is no published human half-life for BPC-157.
Why per-kilogram figures do not convert to a human dose
The recurring confusion online is treating a rodent microg/kg figure as if it scales cleanly to a person. It does not. The Achilles-tendon work used 10 microg, 10 ng, or 10 pg per rat — a four-order-of-magnitude span that still produced effect [1] — which tells you the dose-response in that model is unusually wide, not that any single number is a human target. Interspecies scaling, route differences, and the short animal half-life all sit between a rat figure and a human exposure.
The two-tier evidence frame applies to dosing as much as to efficacy. The only human exposures on record are the pilot infusions of 10 mg and 20 mg IV [5] and the single 10 mg intravesical dose [8] — fixed amounts chosen for those specific feasibility studies, not validated doses. The rodent microg/kg and ng/kg figures belong to the preclinical tier and stay there.
Stability and reconstitution as research handling
BPC-157 is often supplied as a lyophilized acetate salt and reconstituted in a diluent for research handling. Its "stable gastric pentadecapeptide" name reflects reported stability in gastric juice, which underlies oral interest, though human oral pharmacokinetics remain unestablished [2]. Storage and reconstitution practices described in research settings are laboratory handling, not validated clinical protocols, and nothing on this page should be read as preparation instructions.
How long should I stay on BPC-157?
Animal studies use defined dosing courses measured over days to weeks, not open-ended use. There is no validated human protocol for BPC-157, and a 2025 review urges treating it as investigational [6]. "How long to stay on it" therefore has no evidence-based answer for a person — only the fixed-duration designs of the preclinical studies.